Specialty Pharmacy

The Kroger Co today announced it will acquire the outstanding shares of Axium Pharmacy Holdings, Inc, a leading specialty pharmacy, to create a merger of the 2 companies.

The FDA approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

Cardinal Health Specialty Solutions announced today that its specialty pharmacy, OncoSourceRx, has been awarded Specialty Pharmacy Accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.

Avella Specialty Pharmacy, under an agreement with DARA BioSciences, Inc, will be a distribution source for Soltamox, the first and only FDA-approved oral liquid formulation of tamoxifen citrate for the prevention and treatment of breast cancer.

In this Medscape One-on-One video, former FDA Commissioner and former director of the National Cancer Institute Andrew von Eschenbach, MD, suggests using adaptive trial design to test drugs rather than a stepwise approach.

A free source of evidence-based information for health care professionals and for researchers studying liver injury associated with prescription and over-the-counter drugs, herbals, and dietary supplements is now available from the National Institutes of Health.

Celgene Corporation today announced the FDA has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Genentech, Inc, a member of the Roche Group, today announced that the FDA has expanded the approved indication for Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway and compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy's Educational Conference.